A biobank to promote research on new therapies for glioblastoma



(Group picture of the participants to the meeting of 11.01.2019)

This is one of the goals of the Interreg ITA-SLO Trans-Glioma project that sees Elettra Sincrotrone Trieste playing a prominent role


Favouring the development of new therapies for glioblastoma thanks to a transnational multi-operator research platform: this is the purpose of the research team of the Trans-Glioma project. In particular, the team intend to focus their attention on the most resistant glioblastoma stem cells. The data regarding the increase in the incidence of brain cancers – specifically the incurable glioblastoma, which implies a life expectancy of one year and a half for patients diagnosed with it – is very similar in Italy and Slovenia.

The purpose of Trans-Glioma is to increase cooperation among the key operators in the biomedical field (research centres, hospitals, universities and enterprises), promote the transfer of innovative biomedical knowledge and techniques for the diagnosis and treatment of brain tumour, as well as improve the competitiveness and relevance of oncology research at the macroregional level.

In order to take stock of the development of the activities, a meeting with the participation from all the partners took place at the Area Science Park Basovizza campus over the past few days. The partners include: Faculty of Medicine of the University of Ljubljana (lead partner), University Healthcare Authority of Udine, Elettra Sincrotrone Trieste, National Institute of Biology – NIB, BioSistemika, ULSS3 Serenissima Healthcare Authority.

The expected results also include the creation of a joint data bank at the macroregional level, which will allow scientists to work in close cooperation with clinical biomedicine experts, in order to identify patient-specific therapies. The activity of the partners is aimed at guaranteeing an early diagnosis of the tumour and thus a more effective treatment, thanks to a better knowledge of the molecular mechanisms that are at the basis of the disease, which will contribute to improving the quality of life of patients and their families alike.

The expected project results are: the creation of a joint tumour biobank (GLIOBANCA) and the search for and validation of new glioblastoma stem cell biomarkers, which will allow for more precise pharmacological targets.

Trans-Glioma is a project financed by the European Regional Development Fund – 2014-2020 Interreg V-A Italy-Slovenia Programme.


Leo Brattoli, Uff. Stampa AREA Science Park

 

 

 
Last Updated on Tuesday, 05 February 2019 17:46